MX2012004624A - Metodos para tratar canceres positivos para el receptor de androgenos. - Google Patents
Metodos para tratar canceres positivos para el receptor de androgenos.Info
- Publication number
- MX2012004624A MX2012004624A MX2012004624A MX2012004624A MX2012004624A MX 2012004624 A MX2012004624 A MX 2012004624A MX 2012004624 A MX2012004624 A MX 2012004624A MX 2012004624 A MX2012004624 A MX 2012004624A MX 2012004624 A MX2012004624 A MX 2012004624A
- Authority
- MX
- Mexico
- Prior art keywords
- androgen receptor
- receptor positive
- positive cancers
- treating androgen
- positive cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 102000001307 androgen receptors Human genes 0.000 title abstract 4
- 108010080146 androgen receptors Proteins 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25439509P | 2009-10-23 | 2009-10-23 | |
| PCT/US2010/053916 WO2011050353A1 (en) | 2009-10-23 | 2010-10-25 | Method for treating androgen receptor positive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012004624A true MX2012004624A (es) | 2012-08-23 |
Family
ID=43900720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012004624A MX2012004624A (es) | 2009-10-23 | 2010-10-25 | Metodos para tratar canceres positivos para el receptor de androgenos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8835447B2 (https=) |
| EP (1) | EP2490531A4 (https=) |
| JP (1) | JP2013508417A (https=) |
| KR (1) | KR20120095402A (https=) |
| CN (1) | CN102573472A (https=) |
| AP (1) | AP2012006277A0 (https=) |
| AU (1) | AU2010310477A1 (https=) |
| BR (1) | BR112012009262A2 (https=) |
| CA (1) | CA2779309A1 (https=) |
| EA (1) | EA201290208A1 (https=) |
| GE (1) | GEP20146138B (https=) |
| IL (1) | IL219331A0 (https=) |
| MX (1) | MX2012004624A (https=) |
| WO (1) | WO2011050353A1 (https=) |
| ZA (1) | ZA201202557B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201291460A1 (ru) | 2010-05-28 | 2013-11-29 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Олигобензамидные соединения и их применение |
| WO2013023300A1 (en) * | 2011-08-15 | 2013-02-21 | The University Of British Columbia | Inhibitors of androgen receptor activation function-2 (af2) as therapeutics and methods for their use |
| WO2013055793A1 (en) | 2011-10-12 | 2013-04-18 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| WO2013078277A1 (en) | 2011-11-23 | 2013-05-30 | The Board Of Regents Of The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
| US8835493B2 (en) | 2011-11-23 | 2014-09-16 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
| US9828344B2 (en) | 2012-06-01 | 2017-11-28 | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG FRITZ-LIPMANN-INSTITUT e.V. (FLI) | Inhibitors of the notch signaling pathway and secretion for use in medicine |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| LT2872482T (lt) * | 2012-07-13 | 2020-12-28 | Oncternal Therapeutics, Inc. | Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| SMT201900735T1 (it) * | 2012-07-27 | 2020-03-13 | Aragon Pharmaceuticals Inc | Metodi e composizioni per determinare la resistenza a una terapia verso recettore degli androgeni |
| US20160024083A1 (en) * | 2013-03-14 | 2016-01-28 | Health Research, Inc. | Compounds and methods for treating cancers |
| CA2924527C (en) | 2013-09-20 | 2022-07-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compounds for treating prostate cancer |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US11478453B2 (en) | 2016-07-21 | 2022-10-25 | Hadasit Medical Research Services And Development Ltd. | Treatment for glioblastoma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224326A (en) * | 1978-09-21 | 1980-09-23 | Eli Lilly And Company | Immunosuppressive agents |
| AU626881B2 (en) * | 1988-07-14 | 1992-08-13 | F. Hoffmann-La Roche Ag | Benzofused heterocyclics used as pharmaceuticals |
| AU3846395A (en) * | 1994-11-07 | 1996-05-31 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
| US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| US20070299102A1 (en) * | 2004-04-08 | 2007-12-27 | Topo Target A/S | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer |
| CA2570884C (en) * | 2004-06-16 | 2016-04-19 | Jack Arbiser | Carbazole formulations for the treatment of psoriasis and angiogenesis |
| GB0513702D0 (en) * | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| JP2009528383A (ja) * | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Ｐｉ３キナーゼ阻害剤として用いるためのチアゾロン |
| US20100130579A1 (en) | 2006-10-23 | 2010-05-27 | Georgetown University | Cancer therapy |
-
2010
- 2010-10-25 AP AP2012006277A patent/AP2012006277A0/xx unknown
- 2010-10-25 JP JP2012535441A patent/JP2013508417A/ja active Pending
- 2010-10-25 MX MX2012004624A patent/MX2012004624A/es not_active Application Discontinuation
- 2010-10-25 GE GEAP201012711A patent/GEP20146138B/en unknown
- 2010-10-25 KR KR1020127013113A patent/KR20120095402A/ko not_active Withdrawn
- 2010-10-25 EA EA201290208A patent/EA201290208A1/ru unknown
- 2010-10-25 US US13/501,566 patent/US8835447B2/en not_active Expired - Fee Related
- 2010-10-25 CA CA2779309A patent/CA2779309A1/en not_active Abandoned
- 2010-10-25 WO PCT/US2010/053916 patent/WO2011050353A1/en not_active Ceased
- 2010-10-25 CN CN2010800474879A patent/CN102573472A/zh active Pending
- 2010-10-25 EP EP10825802.1A patent/EP2490531A4/en not_active Withdrawn
- 2010-10-25 BR BR112012009262A patent/BR112012009262A2/pt not_active IP Right Cessation
- 2010-10-25 AU AU2010310477A patent/AU2010310477A1/en not_active Abandoned
-
2012
- 2012-04-10 ZA ZA2012/02557A patent/ZA201202557B/en unknown
- 2012-04-22 IL IL219331A patent/IL219331A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2012006277A0 (en) | 2012-06-30 |
| WO2011050353A8 (en) | 2011-07-14 |
| EP2490531A4 (en) | 2013-06-19 |
| JP2013508417A (ja) | 2013-03-07 |
| KR20120095402A (ko) | 2012-08-28 |
| ZA201202557B (en) | 2013-06-26 |
| AU2010310477A1 (en) | 2012-05-03 |
| US20120264771A1 (en) | 2012-10-18 |
| US8835447B2 (en) | 2014-09-16 |
| GEP20146138B (en) | 2014-08-11 |
| WO2011050353A1 (en) | 2011-04-28 |
| EA201290208A1 (ru) | 2012-10-30 |
| IL219331A0 (en) | 2012-06-28 |
| CA2779309A1 (en) | 2011-04-28 |
| BR112012009262A2 (pt) | 2019-09-24 |
| EP2490531A1 (en) | 2012-08-29 |
| CN102573472A (zh) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012004624A (es) | Metodos para tratar canceres positivos para el receptor de androgenos. | |
| MY160399A (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
| PH12014500248B1 (en) | Treatment of breast cancer | |
| TN2015000140A1 (en) | Modulation of androgen receptor expression | |
| GB0920703D0 (en) | Compositions containing satiogens and methods of use | |
| WO2010141738A3 (en) | Compositions and method for inhibiting tumor growth | |
| WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
| MX342951B (es) | Composiciones terapeuticamente activas y su metodo de uso. | |
| MX2020004689A (es) | Tratamiento del cancer con inhibidores de tor cinasa. | |
| WO2011083090A3 (en) | Methods for treating breast cancer | |
| MX346635B (es) | Derivados citotoxicos de la benzodiazepina. | |
| WO2010056378A3 (en) | Extracellular matrix compositions for the treatment of cancer | |
| MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
| NZ601584A (en) | Methods for treating colorectal cancer | |
| TN2012000054A1 (en) | Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent | |
| NZ723971A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| PH12012501680A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| MX2012012992A (es) | Metodos de tratamiento. | |
| MX2013015340A (es) | Composiciones y metodos para el tratamiento de cancer. | |
| MX360774B (es) | Antagonistas de progesterona. | |
| MX2011006725A (es) | Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20. | |
| SG10201810575WA (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| EP2658973A4 (en) | SIRNA FOR INHIBITING HIF1A EXPRESSION AND ANTIBODIES THEREWITH | |
| PH12012501963A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2012071562A3 (en) | Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |